Intensity Therapeutics pauses Phase 3 sarcoma study enrollment; Q1 net loss $3.3M, cash $0.9M

INTENSITY THERAPEUTICS, INC.

Paused new site activations and enrollment in Phase 3 INVINCIBLE-3 sarcoma study due to funding constraints; 23 patients enrolled.
April 2025 public offering raised $2.35M gross ($1.9M net) to prioritize Phase 2 INVINCIBLE-4 breast cancer trial.
Q1 2025 net loss $3.3M (vs $4.6M Q1 2024); cash and equivalents $0.9M as of March 31, 2025.
Eight Swiss sites activated in INVINCIBLE-4; EMA authorized study in France with Unicancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.